COVID-19 Vaccination a Must For Patients With Cancer

It has become imperative that patients with cancer receive a full COVID-19 vaccination with 1 of the 3 approved vaccines as soon as they are able, emphasized Steven Ludlow, PharmD, BCOP, BCPS.¹

“Today, there continues to be an issue with COVID-19,” said Ludlow, a clinical pharmacy specialist at the H. Lee Moffitt Cancer Center in Tampa, Florida, during a presentation at the 39th Annual CFS®. “We just last week crossed the very ominous line of 5 million worldwide deaths. We’re looking pretty good; things are on the mend right now. But we were saying this in June as well, just before we had our brush with [the Delta variant]. We still have a very large pool of [patients with] COVID-19 in the population, and there is also the general unvaccinated status of many undeveloped nations.”

Three COVID-19 vaccines available in the United States: BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), and JNJ-78436735 (Janssen/Johnson & Johnson). BNT162b2 and mRNA-1273 are mRNA-based vaccines, whereas JNJ-78436735 is an andenovirus vector–based product. Both mRNA-based vaccines are administered in a 2-dose series, approximately 28 days apart; JNJ-78436735 is a single-dose vaccine. BNT162b2 is the only vaccine that has received FDA approval for patients who are at least 16 years or older, and the other 2 have been granted emergency use authorization by the FDA.^1,2

According to the most recent National Comprehensive Cancer Network (NCCN) recommendations concerning COVID-19 vaccines for patients with cancer, individuals should receive the vaccine if it is available to them, except for those with solid tumors undergoing major surgery, being treated with hematopoietic cell transplantation (HCT)/cellular therapy, and those with hematologic malignancies receiving intensive cytotoxic chemotherapy.³

The NCCN recommends that patients undergoing HCT or cellular therapy wait until at least 3 months after their treatment to receive a COVID-19 vaccine. Patients with hematologic malignancies undergoing intensive cytotoxic chemotherapy are recommended to delay their vaccination until absolute neutrophil count recovery. Patients with solid tumors being treated with major surgery are recommended to separate their date of surgery from vaccination by a few days, at minimum.³

“The only reason for [patients who have undergone major surgery to delay the vaccine] is not because of surgery itself, [this is to prevent] confusion with fevers that are an adverse effect related [to a vaccine] with one that may be a complication of a major surgery,” Ludlow said.

In terms of vaccine booster doses, almost all patients with cancer should receive a booster dose 6 months after their second dose of an mRNA vaccine. For patients who received the JNJ-78436735 vaccine, a booster dose is recommended 2 months later. The NCCN does not recommend using antibody titers to determine if patients should receive the third dose, the decision should be made based on the underlying cancer, therapy, and other immunocompromising conditions.³

In patients with immunosuppression, a third dose of an mRNA is recommended by the CDC after the standard 2 dose regimen. The third shot is not considered a booster, but rather it is part of a 3-dose series. The third dose should be given 28 days after the initial primary of an mRNA vaccine.⁵

In the moderately to severely immunocompromised, the CDC recommends a booster dose 6-months after the third of the initial series. This primarily concerns patients with hematologic malignancies and patients who receive stem cell transplant. After the fourth dose, if these patients progress to CAR-T cell therapy or stem cell transplant, they should repeat their initial primary series, potentially with a booster dose.¹

“We cannot do direct comparisons; these vaccines were studied in different places, at different times, and with different variants,” Ludlow said. “We saw the data with the mRNA vaccines which were tested originally against the Alpha strain. We saw the South American and South African strains being tested against the Johnson & Johnson products. It’s unfair to put these [data] right next to each other. I would say that the best vaccine is the one that’s in your patient's arm.”

References

1. Ludlow S. COVID-19 vaccine: what the medical oncologist needs to know. Presented at: 39th Annual CFS® Innovative Cancer Therapy for Tomorrow; November 3-5, 2021; New York, NY.
2. FDA Approves First COVID-19 Vaccine. News release. FDA; August 23, 2021. Accessed November 4, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
3. Cancer and COVID-19 vaccination, version 4.0 : recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee. August 30, 2021. Accessed November 4, 2021. https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_70
4. NCCN COVID-19 vaccination guide for people with cancer. National Comprehensive Cancer Network. Accessed November 4, 2021. https://www.nccn.org/docs/default-source/covid-19/covid-vaccine-and-cancer-05.pdf?sfvrsn=45cc3047_2
5. COVID-19 vaccines for moderately to severely immunocompromised people. CDC. Updated October 18, 2021. Accessed November 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html

This article was originally published on OncLive as “COVID-19 Vaccination Remains Imperative for Patients with Cancer”